Biologic therapy(TNF-α antagonists)-induced psoriasis: A cytokine imbalance between TNF-α and IFN-α?

Journal of Clinical Rheumatology

Volumn 14, Issue 6, 2008, Pages 353-356

  Cuchacovich, Raquel ^a,b   Espinoza, Carmen G ^a   Virk, Zia ^a   Espinoza, Luis R ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b LSU Medical Clinics   (United States)

Author keywords

Anti TNF therapy; Autoimmunity; Cytokines; Inflammation; Psoriasis; Psoriatic arthritis

Indexed keywords

ADALIMUMAB; ALPHA INTERFERON; CYTOKINE; FOLIC ACID; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ANAMNESIS; ARTHRITIS; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; DRUG DOSE INCREASE; DRUG WITHDRAWAL; FEMALE; HISTOPATHOLOGY; HUMAN; MALE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RASH; RHEUMATOID ARTHRITIS; SKIN BIOPSY; BIOPSY; CASE REPORT; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; METABOLISM; MIDDLE AGED; PATHOLOGY; PSORIASIS; SKIN;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; BIOPSY; FEMALE; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; PSORIASIS; SKIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 60249095321     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/RHU.0b013e318190dd88     Document Type: Article

References (28)

1. Espinoza LR, van Solingen R, Cuellar ML, et al. Insights into the pathogenesis of psoriasis and psoriatic arthritis. Am J Med Sci. 1998; 316:271-276.
2. Turkiewicz A, Moreland L. Psoriatic arthritis: current concepts on pathogenesis-oriented therapeutic options. Arthritis Rheum. 2007;56: 1051-1066.
3. Candia L, Marquez J, Hernandez C, et al. Toll-like receptor 2 expression is up-regulated in antigen presenting cells from patients with psoriatic arthritis: a pathogenic role for innate immunity. J Rheumatol. 2007;34: 374-379.
4. Villadsen LS, Schuurman J, Beurskens F, et al. Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model. J Clin Invest. 2003;112:1571-1580.
5. Zaba LC, Cardinale I, Gilleaudeau P, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med..2007;204:3183-3194.
6. Sfikakis P, Iliopoulos A, Elezoglou A, et al. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum. 2005;52:2513-2518.
7. Pirard D, Arco D, Debrouckere V, et al. Anti-tumor necrosis factor alpha-induced psoriasiform eruptions: three further cases and current overview. Dermatology. 2006;213:183-186.
8. Carter JD. Tumor necrosis factor inhibition causing psoriasis? A more plausible explanation exists. Ann Rheum Dis. 2006;65:1680-1681.
9. Ritchlin C, Tausk F. A medical conundrum: onset of psoriasis in patients receiving anti-tumor necrosis factor agents. Ann Rheum Dis. 2006;65: 1541-1544.
10. Kary S, Worm M, Audring H, et al. New onset or exacerbation of psoriatic skin lesions in patients with defined rheumatoid arthritis receiving tumor necrosis factor alpha antagonists. Ann Rheum Dis. 2006; 65:405-407.
11. Aslanidis S, Pyrpasopoulou A, Leontsini M, et al. Anti-TNF alpha induced psoriasis: case report of an unusual adverse event. Intern J Dermatol. 2006;45:982-983.
12. Pereira Goncalves D, Laurindo I, Scheinberg MA. The appearance of pustular psoriasis during antitumor necrosis factor therapy. J Clin Rheumatol. 2006;12:262.
13. Cohen D, Bournerias I, Buffard V, et al. Psoriasis induced by tumor necrosis factor alpha antagonist therapy: a case series. J Rheumatol. 2007;34:380-385.
14. deGannes G, GhoreishiM, Pope J, et al. Psoriasis and pustular dermatitis triggered by TNF-alpha inhibitors in patients with rheumatological conditions. Arch Dermatol. 2007;143:223-231.
15. Lee H, Song I-H, Friedrich M, et al. Cutaneous side effects in patients with rheumatic diseases during application of tumor necrosis factor antagonists. Br J Dermatol. 2007;156:486-491.
16. Ubriani R, Van Voorhees A. Onset of psoriasis during treatment with TNF-(alpha) antagonists: a report of three cases. Arch Dermatol. 2007; 143:270-272.
17. Grinblat B, Scheinberg M. The enigmatic development of psoriasis and psoriasiform lesions during anti-TNF therapy: a review. Semin Arthritis Rheum. 2007;37:251-255.
18. Uriarte Itzazalaia E, Hernando I, Prada A, et al. Severe bout of cutaneous psoriasis in a patient with psoriatic arthritis undergoing treatment with infliximab. Clin Exp Rheumatol. 2007;25:659.
19. Bosch RI, Amo Ndel V, Manteca CF, et al. Psoriasis induced by anti-TNF probably not so uncommon. J Clin Rheumatol. 2008;14:128.
20. Bal A, Gurcay E, Aydog E, et al. Onset of psoriasis induced by infliximab. J Clin Rheumatol. 2008;14:128-129.
21. Scheinberg M, Goncalves DP, Laurindo IMM. Anti-TNF agents inducing psoriasis: a recognized adverse effect. J Clin Rheumatol. 2008;14: 130.
22. Ramos-Casals M, Brito-Zeron P, Munoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine. 2007;86:242-251.
23. Tan J, Aphale A, Malaviya R, et al. Mechanisms of action of etanercept in psoriasis. J Investig Dermatol Symp Proc. 2007;12:38-45.
24. Mastroianni A, Minutilli E, Mussi A, et al. Cytokine profiles during infliximab monotherapy in psoriatic arthritis. Br J Dermatol. 2005;153: 531-536.
25. Bovenschen H, Van de Kerkhof M, Gerritsen W, et al. The role of lesional T cells in recalcitrant psoriasis during infliximab therapy. Eur J Dermatol. 2005;15:454-458.
26. Fiorentino DF. The Yin and Yang of TNF alpha inhibition. Arch Dermatol. 2007;143:233-236.
27. Ketikoglou I, Karatapanis S, Elefsiniotis I, et al. Extensive psoriasis induced by pegylated interferon-alpha-2b treatment for chronic hepatitis B. Eur J Dermatol. 2005;15:107-109.
28. Nestle FO, Conrad C, Tun-Kyi A, et al. Plasmacytoid pre-dendritic cells initiate psoriasis through interferon alpha production. J Exp Med. 2005; 202:135-143.